News

Failures in Alzheimer’s Vaccine Efforts Result of Research Errors, Scientist Says, And Suggests Ways of Correcting Them

All failed attempts to produce a viable vaccine against amyloid-beta in Alzheimer’s disease have one thing in common — they all used vaccine adjuvants that elicit the wrong kind of immune response, says Qantu Therapeutics’ president and CSO, Dante J. Marciani, in a sweeping retrospective analysis that covers errors in past and…

Alzheimer’s Diagnosed for a First Time in a HIV-Positive Person, Georgetown Researchers Report

Georgetown University researchers reported what is thought to be the first confirmed case of Alzheimer’s disease in a HIV-positive patient, a 71-year-old man with amyloid deposits in the brain detected by a scan. The case report highlights the importance of further study into HIV-related neurological decline, and raises the possibilty that Alzheimer’s…

Alzheimer’s Disease Mechanism Traced to Genetic Defect That Lowers Levels of a Mitochrondrial Protein

Researchers at two Norwegian institutions found that deficits in the mitochondrial protein PITRM1 led to an accumulation of amyloid-beta, whose deposits in the brain are known to cause Alzheimer’s disease. The findings, drawn from a study of a family with a rare genetic defect, further suggest that mitochondria is a key player in neurodegenerative diseases.

Peptides with Neuroprotective Properties, Identified in Early Study, May Help Alzheimer’s Patients

A family of six mitochondrial small humanin-like peptides (SHLPs) showed promising effects on cell survival and metabolism in preclinical studies of aging, a finding with long-reaching implications for age-related conditions such as Alzheimer’s disease. The findings were announced by the biotechnology company CohBar, which holds the exclusive license for developing SHLPs…